Skip to content
Moojaz — موجز
Search
Menu
HomeRegionsMaghrebAfricaMiddle EastEuropeAsiaAmericasWorldSectionsPoliticsEconomySecurityHealthScienceTechnologyAIEnvironmentCultureSportsSearch
Morocco
File

Novopharma: medicines regulation in Morocco

This dossier follows AMMPS decisions on Novopharma authorisations and corrective measures, distinguishing regulatory status from actual availability.

Last updated : 1 key moments
Stethoscope on white background.
Medical illustration, 2014 archive; does not depict any named product. Sprinno / Wikimedia Commons, CC0, unmodified. — Sprinno / Wikimedia Commons — CC0 1.0 https://creativecommons.org/publicdomain/zero/1.0/ — 28 février 2014, sans modification.

Where things stand

In its 3 November 2026 notice, AMMPS lifts the suspension of nine pharmaceutical products and one health product following assessment of corrective measures.

Reported information

AMMPS lifts suspension of nine Novopharma pharmaceutical products

AMMPS announced in a notice published on 3 November 2026 that it was lifting suspensions affecting nine Novopharma pharmaceutical products and the registration certificate of one health product.

Stethoscope on white background.
Medical illustration, 2014 archive; does not depict any named product. Sprinno / Wikimedia Commons, CC0, unmodified. — Sprinno / Wikimedia Commons — CC0 1.0 https://creativecommons.org/publicdomain/zero/1.0/ — 28 février 2014, sans modification.

The agency says it assessed corrective and preventive actions taken after its 22 July decision. The list includes presentations of Flustaph, Torva and Dispamox, together with Roxam and Agiderm. Arthrodont Classic is the health product concerned.

The decision addresses the regulatory status of the listed products; the notice does not provide a pharmacy restocking timetable.

Sources 2